Implanet SA (IM11) Price & Analysis

― Followers

IM11 Stock Chart & Stats

€0.28

>-€0.01(-1.68%)

At close: Jan 08 4:00 PM EST

€0.28

>-€0.01(-1.68%)

Day’s Range― - ―

52-Week Range€0.13 - €0.42

Previous CloseN/A

Volume0.00

Average Volume (3M)4.40K

Market Cap

€24.62M

Enterprise Value€28.91

Total Cash (Recent Filing)€3.01M

Total Debt (Recent Filing)€5.92M

Price to Earnings (P/E)―

Beta-0.25

Next Earnings

Sep 15, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.03

Shares Outstanding143,818,970

10 Day Avg. Volume3,845

30 Day Avg. Volume4,401

Financial Highlights & Ratios

PEG Ratio0.35

Price to Book (P/B)70.59

Price to Sales (P/S)2.29

P/FCF Ratio-13.27

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Sustained Revenue GrowthConsistent multi-year revenue growth indicates expanding adoption of Implanet’s implant systems and deeper penetration of target hospital/distributor channels. This top-line momentum supports scalable unit economics and provides a larger base to absorb fixed costs as the business seeks operating leverage.

Improving Gross MarginsA sharp margin improvement suggests better pricing mix or cost control in manufacturing and distribution. Higher sustainable gross margins increase the odds that revenue growth will translate into operating profitability, enabling reinvestment in R&D and commercial expansion without as much margin erosion.

Durable Medical Device Business ModelImplanet’s product set (implants + instruments) targets hospitals and surgeons with recurring consumable demand and platform stickiness. Installed-base dynamics and repeatable procedure-driven purchases create predictable revenue streams and higher lifetime customer value versus one-off product models.

Bears Say

Very High Leverage And Thin EquityA capital structure dominated by debt with minimal equity leaves limited buffer against operational setbacks and increases refinancing risk. Persistent losses could rapidly erode liquidity, constrain strategic investments, and force dilutive or costly financing, undermining long-term financial flexibility.

Negative Operating And Free Cash FlowSustained negative operating and free cash flow implies dependence on external funding to sustain growth. Until operations generate positive cash, the company will face recurring financing needs that can dilute shareholders, restrict capex/R&D, and expose operations to funding-cycle volatility.

Persistent Net LossesDespite revenue and margin improvements, ongoing substantial net losses indicate management has not yet converted top-line gains into sustainable bottom-line results. Continued losses pressure equity, limit reinvestment capacity, and mean the business must prove operating leverage to justify long-term viability.

IM11 FAQ

What was Implanet SA’s price range in the past 12 months?

Implanet SA lowest stock price was €0.13 and its highest was €0.42 in the past 12 months.

What is Implanet SA’s market cap?

Implanet SA’s market cap is €24.62M.

When is Implanet SA’s upcoming earnings report date?

Implanet SA’s upcoming earnings report date is Sep 15, 2026 which is in 49 days.

How were Implanet SA’s earnings last quarter?

Implanet SA released its earnings results on Feb 24, 2026. The company reported -€0.017 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is Implanet SA overvalued?

According to Wall Street analysts Implanet SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Implanet SA pay dividends?

Implanet SA does not currently pay dividends.

What is Implanet SA’s EPS estimate?

Implanet SA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Implanet SA have?

Implanet SA has 143,818,970 shares outstanding.

What happened to Implanet SA’s price movement after its last earnings report?

Implanet SA reported an EPS of -€0.017 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.723%.

Which hedge fund is a major shareholder of Implanet SA?

Currently, no hedge funds are holding shares in DE:IM11

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Implanet SA

Implanet S.A., together with its associated companies, is dedicated to the research, development, manufacturing, and commercialization of spinal and orthopedic medical implants. The firm's product portfolio addresses both spinal and knee needs. Its spinal offerings encompass various posterior fixation systems, including the Jazz PF, Jazz Evo, Jazz Cap SP, Jazz Passer, Jazz Lock, Jazz Claw, Jazz Frame, and ISS-Jazz Screw lines. Furthermore, Implanet S.A. provides knee prostheses, which are marketed under the Madison brand. The company has a significant strategic alliance with Shanghai Sanyou Medical Co, Ltd. Established in 2006, Implanet S.A. operates from its headquarters in Martillac, France.